Klinik und Poliklinik für Geburtshilfe und Frauengesundheit
Klinikum / Johannes Gutenberg-Universität Mainz
Heimes, Anne-Sophie; Almstedt, Katrin; Krajnak, Slavomir et al.
Prognostic Impact of LAG-3 mRNA Expression in Early Breast CancerBIOMEDICINES. Bd. 10. H. 10. 2022
Bartlett, J. M.; Xu, K.; Wong, J. et al.
Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR plus breast cancer in the TEAM trialANNALS OF ONCOLOGY. Bd. 33. H. 7. 2022 S. S602-S602
Harter, Philipp; Sehouli, Jalid; Vergote, Ignace et al.
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer (vol 385, pg 2123, 2021)NEW ENGLAND JOURNAL OF MEDICINE. Bd. 386. H. 7. 2022 S. 704-704
Lueftner, Diana; Brucker, Cosima; Decker, Thomas et al.
Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Results of fourth interim analysis (IA) from RIBANNA.JOURNAL OF CLINICAL ONCOLOGY. Bd. 40. H. 16. 2022
Luftner, Diana; Brucker, Cosima; Decker, Thomas et al.
Real-world efficacy of ribociclib plus aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) locally advanced or metastatic breast cancer: Fourth interim analysis from the RIBANNA studyCANCER RESEARCH. Bd. 82. H. 4. 2022
Schwab, Roxana; Droste, Annika; Stewen, Kathrin et al.
Resilience as a Source of Easement to Health-Related Worries in Women at Increased Risk for Breast or Ovarian Cancer During the COVID-19 PandemicINTERNATIONAL JOURNAL OF GENERAL MEDICINE. Bd. 15. 2022 S. 7039-7052
Woelber, Linn; Hampl, Monika; Eulenburg, Christine Zu et al.
Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva StudyCANCERS. Bd. 14. H. 2. 2022
Lecuru, F.; Sehouli, J.; Vergote, I. B. et al.
Role of CA125 in patients included in the DESKTOP III/ENGOT-ov20 trialANNALS OF ONCOLOGY. Bd. 33. H. 7. 2022 S. S809-S809
Heitz, F.; Sehouli, J.; Fotopoulou, C. et al.
Role of cytoreductive Surgery in Patients who did not undergo Surgery for first Recurrence: A Sub-analysis of the DESKTOP III StudyGEBURTSHILFE UND FRAUENHEILKUNDE. Bd. 82. H. 10. 2022 S. E86-E87
Feiten, Stefan; Scholl, Isabelle; Duennebacke, Jan et al.
Shared decision-making in routine breast cancer care in Germany-A cross-sectional studyPSYCHO-ONCOLOGY. Bd. 31. H. 7. 2022 S. 1120-1126